Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial.

@article{Villar2020DexamethasoneTF,
  title={Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial.},
  author={Jes{\'u}s Villar and Carlos Ferrando and Domingo Mart{\'i}nez and Alfonso Ambr{\'o}s and Tom{\'a}s Mu{\~n}oz and Juan Alfonso Soler and Gerardo Aguilar and Francisco Alba and Elena Gonz{\'a}lez-Higueras and Lu{\'i}s A Conesa and Carmen Mart{\'i}n-Rodr{\'i}guez and Francisco J. D{\'i}az-Dom{\'i}nguez and Pablo Serna-Grande and Rosana Rivas and Jos{\'e} Ferreres and Javier F. Belda and Luc{\'i}a Capilla and Alec Tallet and Jos{\'e} Manuel A{\~n}{\'o}n and Rosa Lidia Fern{\'a}ndez and Jes{\'u}s Mar{\'i}a Gonz{\'a}lez-Mart{\'i}n},
  journal={The Lancet. Respiratory medicine},
  year={2020}
}

Figures and Tables from this paper

Use of glucocorticoids in patients with acute respiratory distress syndrome: a meta-analysis and trial sequential analysis
TLDR
Among patients with ARDS, use of glucocorticoids is associated with a significant reduction in mortality and duration of mechanical ventilation, without increased risk of hospital-acquired infections.
Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled superiority trial
TLDR
It is postulated that adjunctive treatment of established ARDS caused by COVID-19 with intravenous dexamethasone might change the pulmonary and systemic inflammatory response and thereby reduce morbidity, leading to a decrease in duration of mechanical ventilation and in mortality.
Decreased mortality in acute respiratory distress syndrome patients treated with corticosteroids: an updated meta-analysis of randomized clinical trials with trial sequential analysis
TLDR
The pooled analysis revealed that glucocorticoid use was associated with reduced mortality and might result in reduced mortality in patients with ARDS; however, the optimal dose and duration of steroid therapy remains unknown and further studies are needed.
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.
TLDR
Among patients with COVID-19 and moderate or severe ARDS, use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator-free days over 28 days.
Corticosteroids in adult respiratory distress syndrome – an inconvenient truth?
TLDR
The use of corticosteroids outside a randomisation process in randomised clinical trials may be more common than appreciated and needs to be routinely reported.
Steroid treatment in patients with acute respiratory distress syndrome: a systematic review and network meta-analysis
TLDR
It is suggested that the effect of steroids on the outcome in patients with ARDS might depend on the type of the steroid drug administered, and further studies are needed to identify the optimal type and dosage.
The Controversy About the Effects of Different Doses of Corticosteroid Treatment on Clinical Outcomes for Acute Respiratory Distress Syndrome Patients: An Observational Study
TLDR
Appropriate dose of corticosteroids may be beneficial for ARDS patients through improving the oxygenation and moderately inhibiting inflammatory response and the benefits and risks should be carefully weighed when using high-dose Corticosteroid for AR DS.
Corticosteroids for patients with acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials.
TLDR
It is suggested that systemic corticosteroids may potentially improve mortality, ventilator duration, and VFD in patients with ARDS, but caution in the actual clinical application of these results is recommended.
Corticosteroid treatment for early acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials
TLDR
Prolonged corticosteroid treatment in early ARDS improved the survival outcomes and several endpoints such as ventilator-free days and adverse events were set as the secondary outcomes.
Pharmacological management of adult patients with acute respiratory distress syndrome
TLDR
A precision approach for ARDS, whereby therapies are specifically targeted to patients most likely to benefit, has been proposed, however, the application of this approach seems to be a difficult task.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 57 REFERENCES
Evaluating the efficacy of dexamethasone in the treatment of patients with persistent acute respiratory distress syndrome: study protocol for a randomized controlled trial
TLDR
It is postulated that adjunctive treatment of persistent ARDS with intravenous dexamethasone might change the pulmonary and systemic inflammatory response and thereby reduce morbidity, leading to a decrease in duration of mechanical ventilation and a decreases in mortality.
Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial.
TLDR
In this study, prolonged administration of methylprednisolone in patients with unresolving ARDS was associated with improvement in lung injury and MODS scores and reduced mortality.
Efficacy and Safety of Corticosteroids for Persistent Acute Respiratory Distress Syndrome
TLDR
A multicenter, randomized controlled trial of corticosteroids in patients with persistent acute respiratory distress syndrome found that methylprednisolone improved survival and biochemical markers of inflammation and fibroproliferation, and infectious complications.
Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome*
TLDR
This post hoc analysis shows that a 7-day treatment with low doses of corticosteroids was associated with better outcomes in septic shock-associated early ARDS nonresponders, but not in responders and not inseptic shock patients without ARDS.
Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome.
TLDR
Among patients with moderate-to-severe ARDS who were treated with a strategy involving a high PEEP, there was no significant difference in mortality at 90 days between patients who received an early and continuous cisatracurium infusion and those who were treating with a usual-care approach with lighter sedation targets.
Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial.
TLDR
Methylprednisolone-induced down-regulation of systemic inflammation was associated with significant improvement in pulmonary and extrapulmonary organ dysfunction and reduction in duration of mechanical ventilation and ICU length of stay.
The ALIEN study: incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation
TLDR
These findings support previous estimates in Europe and are an order of magnitude lower than those reported in the USA and Australia.
Prone positioning in severe acute respiratory distress syndrome.
TLDR
In patients with severe ARDS, early application of prolonged prone-positioning sessions significantly decreased 28-day and 90-day mortality.
Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS
TLDR
Moderate-to-high quality evidence is shown that glucocorticoid therapy is safe and reduces time to endotracheal extubation, duration of hospitalization, mortality, and mortality and increases the number of days free from mechanical ventilation.
...
1
2
3
4
5
...